| 000 | 01348nam a2200229 4500 | ||
|---|---|---|---|
| 001 | 387625 | ||
| 010 | _a9789291683154 | ||
| 090 | _a387625 | ||
| 100 | _a20090420d2008 y0pory50 ba | ||
| 101 | _aeng | ||
| 200 |
_aTowards a better understanding of drug-related public expenditure in Europe _fEuropean Monitoring Centre for Drugs and Drug Addiction |
||
| 210 |
_aLuxembourg _cOffice for Official Publications of the European Communities _d2008 |
||
| 215 |
_a28 p. _d30 cm |
||
| 330 | _aIntroductory note and acknowledgements. Introduction. Drug-related economic evaluation: key issues. Efficiency. Addressing efficiency through economic evaluation. Perspectives in economic evaluation. Cost studies. A particular perspective on costing: public expenditure. Drug-related public expenditure in Europe. Labelled expenditure. Non-labelled expenditure. Total drug-related expenditure in Europe. Conclusions and recommendations. Limitations of the study and future developments. The flip side of drug-related public expenditure. References. Glossary. | ||
| 606 |
_aESTUPEFACIENTE _9343050 |
||
| 606 |
_aDESPESAS PĂBLICAS _9246095 |
||
| 606 |
_aOEDT _9321506 |
||
| 710 |
_aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION _9351987 |
||
| 955 | _xOferta | ||